Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OCATA THERAPEUTICS -- Ignore unavailable to you. Want to Upgrade?

To: Da Rookie who wrote (93)	9/25/2013 12:15:00 PM
From: Savant	Respond to of 134

Advanced Cell Technology to Present at 2013 Aegis Capital Healthcare Conference Sep 25, 2013 09:40:00 (ET) MARLBOROUGH, Mass., Sep 25, 2013 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT";OTCQB:ACTC), a leader in the field of regenerative medicine, today announced that Chairman and CEO Gary Rabin will present a corporate overview at the 2013 Aegis Capital Healthcare Conference. The presentation will take place on Thursday, September 26 at 11 am PT at The Encore at Wynn Las Vegas in Las Vegas, NV. A question and answer session will follow Mr. Rabin's formal remarks. Advanced Cell Technology CFO and Executive Vice President of Corporate Development, Ted Myles, will present at the StemCells & Regenerative Medicine Congress. The presentation will take place on Monday, September 30th at 11:40 am ET at the Hyatt Regency in Cambridge, MA. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com or connect with the Company on Facebook, Twitter, LinkedIn, Google+, and YouTube. Forward-Looking Statements

To: Da Rookie who wrote (93)

6/25/2014 12:41:08 AM

From: Savant

Respond to of 134

Advanced Cell Technology Appoints Paul K. Wotton, Ph.D, President and Chief Executive Officer

Industry Veteran to Lead Company's Growth and Clinical Expansion

MARLBOROUGH, Mass.--(BUSINESS WIRE)--June 24, 2014--

Advanced Cell Technology, Inc. ("ACT")(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Paul Wotton, Ph.D., to the position of President and Chief Executive Officer. Dr. Wotton is a highly regarded veteran of the biopharmaceutical industry and has a track record of leading companies to clinical, financial and commercial success. Dr. Wotton joins ACT from Antares Pharma Inc. (NASDAQ:ATRS), where he served as President and CEO since October, 2008.

"We are very pleased to attract an executive of Paul's caliber. His experience in leading Antares from a biopharmaceutical company in early-stage clinical development to a commercial enterprise approaching profitability should prove invaluable as ACT moves its scientific platform through the clinic and focuses on commercial and partnership opportunities," said Michael Heffernan, Chairman of the Board of Directors of ACT. "With the vast majority of the legacy issues now behind the company, Paul is joining at an exciting time as we move our RPE program for the treatment of SMD/AMD into Phase 2 development. I would also like to thank the management team, led by Interim President Ted Myles, for their excellent leadership through this transition period."

Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham. Dr. Wotton is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada.

"I am delighted to join ACT at this pivotal time in its growth. The company is now ready to pursue its Phase II clinical trials for AMD and SMD, Phase I for MMD and to advance the novel programs in its pre-clinical pipeline," commented Dr. Wotton. "Cell based therapies are an exciting opportunity and ACT is at the forefront of these developments. I believe we have an incredible opportunity to bring these novel therapies to patients in need and I am very pleased to be part of this initiative."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., (ACT) is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company's most advanced products are in clinical trials for the treatment of dry age-related macular degeneration, Stargardt's macular degeneration and myopic macular degeneration. ACT's preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company's intellectual property portfolio includes pluripotent stem cell platforms -- hESC and induced pluripotent stem cell (iPSC) -- and other cell therapy research programs. For more information, visit www.advancedcell.com.

Forward-Looking Statements